© 2020 Lucid Diagnostics 

One Grand Central Place, Suite 4600 

New York, NY 10165 

Email : info@LucidDX.com

 

212-949-4319 

  • White Twitter Icon
  • White LinkedIn Icon

News & Press

PRESS RELEASE

March 2, 2020

PAVmed Subsidiary Lucid Diagnostics Partners with

Universityof Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients

Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and frequent invasive endoscopies

NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has entered into a clinical trial research agreement with the University of

Pennsylvania (“Penn”) for a clinical trial designed to evaluate whether Lucid’s EsoCheck™ Esophageal Cell

Collection Device with Collect+Protect™ Technology (“EsoCheck”) provides a less invasive, more efficient, and costeffective

alternative to endoscopic biopsies in the management of patients with Eosinophilic Esophagitis.

PRESS RELEASE

February 11, 2020

U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device

Designation for its EsoGuard Esophageal DNA Test

NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company’s majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its EsoGuard™ Esophageal DNA Test on esophageal samples collected using its EsoCheck™ Cell Collection Device in a prevalent well-defined group of patients at elevated risk for esophageal dysplasia due to chronic

gastroesophageal reflux disease (GERD).

PRESS RELEASE

 September 5, 2019 

PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and six months ended June 30, 2019 and provided a

business update.

“The second quarter and early third quarter has been a period of solid progress for PAVmed,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “We advanced our lead product portfolio on multiple fronts, including the recent successful completion of all procedures in the CarpX™ clinical safety study. This progress has set up the remainder of the year to be an exciting period of major milestones, including the full U.S. commercial launch of EsoGuard™ and the upcoming FDA 510(k) re-submission of CarpX.”

PRESS RELEASE

April 4, 2019

PAVmed Reports Fourth Quarter 2018 Financial Results and Provides Business Update 

 PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and 12 months ended December 31, 2018 and provided a business update. 

“I am very pleased with the progress PAVmed has made during what has been a very active and productive fourth quarter of 2018 and in recent months,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “We have achieved several important milestones across our lead product ...

PRESS RELEASE

May 14, 2018

PAVmed and Case Western Reserve University Finalize

Definitive Licensing Agreement for Groundbreaking

EsoCheck Technology

PAVmed subsidiary Lucid Diagnostics Inc. secures exclusive worldwide license for EsoCheck

Rapid, highly accurate, office-based test utilizes a novel, non-invasive

cell-sampling device coupled with proprietary DNA biomarkers to

detect Barrett’s Esophagus, precursor to the most common and lethal form of esophageal cancer, caused by acid reflux

First commercial product projected to launch in the U.S. in the first

quarter of 2019, eventually targeting up to 50 million at-risk patients

PRESS RELEASE

February 20, 2020

PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate

Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™

Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal cancer develops.

 

NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has entered into a sponsored research agreement with the Fred Hutchinson Cancer Research Center (“Fred Hutchinson”) at the University of Washington in Seattle, WA to evaluate Barrett’s Esophagus (BE) progression biomarkers in patients using Lucid’s EsoCheck™ Esophageal Cell Collection Device with Collect+Protect™ Technology.

PRESS RELEASE

December 19, 2019

PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test

First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer

First patients to undergo testing today at gastroenterology center of excellence.

NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”) has launched its EsoGuardTM Esophageal DNA Test as a Laboratory Developed Test (LDT), after completing CLIA/CAP certification of the test at Lucid’s commercial diagnostic laboratory partner ResearchDx Inc. dba Pacific Dx (“ResearchDx”), headquartered in Irvine, CA. EsoGuard is the first such DNA test designed to facilitate the diagnosis of Barrett’s Esophagus (BE) and related precursors to highly lethal esophageal adenocarcinoma (EAC).

PRESS RELEASE

 June 24, 2019 

 PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™ 

 PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received 510(k) marketing clearance for its EsoCheck Cell Collection Device™ (“EsoCheck”) from the U.S. Food and Drug Administration (FDA). 

“I have spent my career seeking to improve the care of patients with gastroesophageal reflux disease and Barrett’s Esophagus and to prevent deaths from esophageal cancer. I have actively participated in the development of key advances..."

PRESS RELEASE

February 28, 2019

PAVmed Subsidiary Lucid Diagnostics Launches World-Class Medical Advisory Board and Appoints Chief Medical Officer 

 PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its subsidiary, Lucid Diagnostics Inc. (“Lucid”), has launched a world-class medical advisory board (MAB) consisting of internationally renowned experts in gastroesophageal reflux disease (GERD), Barrett’s Esophagus (BE) and esophageal cancer and has appointed veteran life sciences industry executive David Wurtman, MD, MBA, as its Chief Medical Officer. 

PRESS RELEASE

April 24, 2018

PAVmed Signs Letter of Intent with Case Western Reserve University to Commercialize Groundbreaking

EsoCheck Technology

PAVmed subsidiary to receive exclusive worldwide license to commercialize EsoCheck

 

Five-minute, office-based alternative to endoscopy utilizes highly accurate DNA biomarkers to detect Barrett’s Esophagus, the precursor to a common highly lethal form of esophageal cancer

Will target up to 50 million at-risk patients and an estimated addressable market of several billion dollars

PRESS RELEASE

February 18, 2020

PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product Pipeline

Disposable single-use device designed to provide safer, more efficient and cost-effective ablation of dysplastic Barrett’s Esophagus, complementing Lucid Diagnostics’ EsoGuard™ and EsoCheck™ products.

NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has added the EsoCure™ Esophageal Ablation Device with Caldus™ Technology to its commercial product pipeline.

PRESS RELEASE

November 21, 2019

PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update

NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and nine months ended September 30, 2019 and provided a business update.

“The third quarter and recent weeks have been highly productive as we secured financing on favorable terms and approach exciting upcoming milestones which include the commercial launch of EsoGuard,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer.

PRESS RELEASE

 May 21, 2019 

PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update 

“The first quarter and recent weeks have been perhaps the most exciting period in PAVmed’s history, anchored by a long-anticipated major clinical milestone for our leading product, multiple technological breakthroughs across our portfolio and several key patent allowances,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. 

PRESS RELEASE

November 29, 2018

PAVmed Subsidiary Lucid Diagnostics Files 510(k) Submission with FDA for EsoCheck™ Cell Collection Device 

 PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of a 510(k) premarket notification submission for the EsoCheck™ Cell Collection Device (CCD) which its subsidiary Lucid Diagnostics filed on November 21, 2018. 

Media & Corporate Contacts

INVESTORS


Mike Havrilla
Director of Investor Relations
JMH@PAVmed.com

 

 

MEDIA​


Shaun O’Neil
Chief Commercial Officer
SMO@PAVmed.com